A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02222922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647020 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Study identification
- NCT ID
- NCT02222922
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Interventions
- PF-06647020 Q3W Drug
- fluconazole Drug
- PF-06647020 Q2W Drug
- PF-06647020 combined with Avelumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 16, 2014
- Primary completion
- Nov 4, 2019
- Completion
- Nov 4, 2019
- Last update posted
- Dec 16, 2020
2014 – 2019
United States locations
- U.S. sites
- 15
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| Scottsdale Healthcare Hospitals DBA HonorHealth | Scottsdale | Arizona | 85258 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University of California Davis Medical Center | Sacramento | California | 95817 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| Stanford Hospital and Clinics | Stanford | California | 94305 | — |
| University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| START Midwest | Grand Rapids | Michigan | 49503 | — |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | 78229 | — |
| Inova Fairfax Hospital Woodburn GYN Infusion Center | Annandale | Virginia | 22003 | — |
| Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates (MAGOPSA) | Annandale | Virginia | 22003 | — |
| Fairfax Radiological Consultants | Fairfax | Virginia | 22031 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Inova Loudon Hospital | Leesburg | Virginia | 20176 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02222922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02222922 live on ClinicalTrials.gov.